Drug Trial Radar · NCT06205628
Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
28
Actual
Start
Mar 21, 2024
Primary completion
Oct 6, 2026
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- ADARx Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- ADARx Australia Pty Ltd
- First posted
- Jan 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ADX-850 in participants with hypertension.
Conditions
- Hypertension
- Hypertension,Essential
Interventions
ADX-850Drug
siRNA duplex oligonucleotide
PlaceboDrug
Saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of ADX-850 in Participants with HypertensionTime frame: 365 days
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Clinitrials Pty Ltd
Perth, Australia
CMAX Clinical Research
Adelaide, South Australia, Australia
Linear Clinical Research
Nedlands, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.